Key facts
- Nuevocor’s last known valuation is $30.1M (Nov 2022).
- It has raised $80.6M; the latest was Later Stage VC ($45.0M) in May 2025.
- Notable investors include EDBI, SEEDS Capital, Highlight Capital, Kurma Partners, Boehringer Ingelheim Venture Fund — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Nuevocor
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuevocor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuevocor
Operator of a biotechnology firm intended to develop gene therapies for the treatment of cardiovascular disease. The company focuses on genetic cardiomyopathies characterized by aberrant mechanobiology, which seeks to treat by modulating mechanical force transduction, enabling doctors to restore cardiac function in diseased hearts.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2020
- Employees
- 29
- Website
- nuevocor.com/
- Ownership
- Privately Held (backing)
Nuevocor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuevocor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuevocor in its N-PORT filings yet. We sweep new filings monthly.